Medx Health Blockbuster Potential !

nur 2,3 mio börsenwert versprechen bei einer vollzugsmeldung zum investor renditechancen  

Kanada mit guten Umsätzen auf Tageshoch und damit neuem Jahreshoch geschlossen.
Schlußkurs über 200 Tagelinie (1. SK ü. GD 200 seit fast 12 Monaten) !
Charttechnisch freigeschossen  

da wird es spannend in Sachen News. Die starken Umsätze der letzten Tage. der steigende Kurs der Deal mit dem Investmenthaus und die extrem niedrige Börsenbewertung versprechen hier gute Chancen auf neue Jahreshochs der Aktie. Der Kurs dürfte also deutlich nziehen. Ziel zwischen. 0,5 - 0,8 Potential sehr hoch. kurzfristig  

MedX Laser und die MedX Phototherapie vor dem absoluten Durchbruch. Die MedX Laser
Technologie sowie Patente Millionen Marktwert. Laser gegen Krebs für MedX Laser eine Meilenstein
News.

http://www.uchospitals.edu/news/2013/20130305-focal-therapy.html


Focal therapy offers middle ground for some prostate cancer patients
March 5, 2013
Men with low-risk prostate cancer who previously had to choose between aggressive treatment, with the potential for significant side effects, and active surveillance, with the risk of disease progression, may have a new option. Focal laser ablation uses precisely targeted heat, delivered through a small insertion and guided into the prostate by magnetic resonance imaging, to burn away cancerous cells in the prostate.
A small, phase 1 trial, published early online in the journal "Radiology", found that this approach, designed to treat just the diseased portion of the prostate rather than removing or irradiating the entire gland, is safe and can be performed without the troubling complications associated with more aggressive therapies.
None of the nine men treated in the study had a significant side effect. Six months after therapy, seven of the nine patients (78%) no longer had evidence of cancerous tissue in biopsies of the treated area.
“Focal therapy is the male version of a lumpectomy for breast cancer,” said study author Scott Eggener, MD, associate professor of surgery at the University of Chicago Medicine. “Rather than removing the entire organ, we are testing this less-invasive way of destroying just the cancer and leaving healthy tissue in place.”
“This experimental approach appears to combine the most attractive element of treatment, eradication of the cancer, with the most appealing element of active surveillance, maintaining quality of life,” said Aytekin Oto, MD, professor of radiology and chief of abdominal imaging at the University of Chicago Medicine. “These early safety results are promising, but we definitely need longer-term data.”
More than 2 million American men have been diagnosed with prostate cancer. Due to prostate specific antigen testing (PSA), most of these cancers are detected early, long before they cause symptoms. Because this cancer occurs primarily in older men, treatment with radiation or surgery is not always necessary as these are man are much more likely to die from another cause than from prostate cancer.
But many healthy men who are relatively young, with a life expectancy greater than 10 years, are not comfortable deferring treatment of a potentially lethal disease. Surgery and radiation can often cure the cancer, but can cause side effects, such as incontinence, impotence and decreased bowel function.
This study enrolled nine men with biopsy-confirmed, low-risk prostate cancers (Gleason score 6 or 7, less than 12 mm of cancer) with an MRI of the prostate showing a small area of cancer. Patients were treated under conscious sedation while lying in an MRI scanner. After injecting a local anesthetic, the physicians inserted a small catheter across the perineum and used it to guide a tiny optical fiber, the laser and a cooling device into the prostate.
Under MRI guidance, the laser was positioned within the cancer and used to heat the area to a temperature that would kill cancer cells. The team checked the temperatures outside the treatment region every five seconds to protect healthy tissue, especially those near critical structures such as the urethra and rectal wall.
The entire procedure took less than four hours. That decreased to 2.5 hours as the team gained experience. The actual heat treatment averaged 4.3 minutes. All patients left the hospital the same day.
No patient had a major complication or a serious adverse effect. Average scores for urinary or sexual function were not significantly different one, three or six months after treatment. No patient had symptoms of rectal wall damage.
Biopsies of the treated areas six months after the procedure found no evidence of prostate cancer in seven of the nine patients (78%). The other two patients had small (2.5 mm and 1 mm) remaining cancers.
These are preliminary results, the authors caution, following a small number of patients for a short time. It will take much longer follow-up, the authors say, to fully evaluate this approach.
Focal laser ablation is the latest in a series of efforts to target just the cancer cells and preserve normal areas of prostate. It appears to offer “measurable advantages over other ablative therapies for focal prostate treatment, namely that we can visualize our treatment as it is happening,” according to the study authors.
Laser-induced heating can destroy cancer cells with little damage beyond the precisely targeted zone. The approach is well suited for prostate tissue and can be carefully watched in real-time with magnetic resonance imaging, which can also monitor the generation and consequences of the heat treatment.
A phase 2 trial of this procedure, sponsored by the National Institutes of Health, is now underway at the University of Chicago Medicine. The physicians hope to enroll 27 patients. Details are available at the NIH’sClinicalTrials.gov
 website, identifier: NCT01792024
.
The paper, “MR Imaging-guided Focal Laser Ablation for Prostate Cancer: Phase I Trial,” appears as an early release in "Radiology
". The study was supported by a research grant from the Partnership for Cures Foundation and by Visualase, the manufacturer of the imaging software and laser ablation tools used in this study. Additional authors include Gregory Karczmar and Walter Stadler of the University of Chicago, and Ila Sethi, Roger McNichols, Karko Ivancevic and Sydeaka Watson of Visualase.
*The University of Chicago Medicine* 
Communications 
950 E. 61st Street, Third Floor 
Chicago, IL 60637 
Phone (773) 702-0025 Fax (773) 702-3171
Related Links
 * Scott Eggener, MD

 * Aytekin Oto, MD

 * Prostate Cancer Care
Social Media
 * Twitter

 * Facebook

 * Science Life Blog

 * YouTube
Press Contact
*John Easton* 
(773) 702-0025 
john.easton@uchospitals.edu  

Das ding ist ein ganz schlechter Push.

 

Man kann schön am Volumen erkennen das es ein "Fake" ist.

Anders gesagt kurz nach dem Starken Volumen ging kurz drauf mehr Volumen wieder heraus obwohl der kurs weiter steigt!

Hier will jemand ganz klar ein paar Ahnungslose anlocken!

Finger weg!!

Das ganze nochmal in einer einfachen Grafik:

Bilderquelle: http://www.finanzen.net/chart/MedX_Health

 

 

Du nennst das Push wer sich allerdings nicht nur oberflächlich mit dem Unternehmen beschäftigt hat weiß im übrigen das der Byron deal positiv gelaufen scheint.

Sämtliche Umsätze sind an der kanadischen Heimatborse. Intraday Umsätze von ca. 4 Millionen infolge guter News als Push zu bezeichnen ist einfach nur peinlich. Byron war eben erfolgreich und ein paar insider gibt es immer. Im übrigen kann jeder seine Meinung schreiben. Auch Kritiker sind gern willkommen . Doch bevor man kritisiert sollte man sich informieren. Danke


Byron will, over a two-month period commencing on the date of signature of the agreement, facilitate MDX's access to capital markets, and identify potential acquisition, divestiture or merger opportunities. In addition, Byron will provide strategic advice to MDX with the intent to maximize shareholder value, assist with introduction to potential strategic investors and assist MDX in structuring future transactions.

 

Also jetzt mal Butter bei "die " Fische glaubst du das was du geschrieben hast wirklich oder willst du jemanden veräppeln. Was ist denn in der Infusion drin ?

 

MedX's HandySana 211 mobile Health Projekt erfährt eine totale Neubewertung. 26 Mrd. Dollar Markt in nur 5 Jahren


http://www.medxhealth.com/documents/Handy_sana_211_Blurb.pdf

http://www.crn.de/netzwerke-tk/artikel-98569.html

Mobility-TrendMarkt für mobile Gesundheits-Apps boomt

11.03.2013

Technische Medizinlösungen werden in steigendem Maße als Apps angeboten. Bis 2017 soll der Markt 26 Milliarden US-Dollar schwer werden.Arztsuche-App: »Verbraucher nutzen Smartphones zur Verbesserung der Gesundheitsversorgung«. Der Markt für sogenannte mHealth Dienstleistungen hat die Phase der Kommerzialisierung erreicht. In vier Jahren werden die Umsätze hier 26 Milliarden US-Dollar erreichen. Die Zahl stammt aus dem neuen Bericht »GlobalMobile Health Market Report 2013-2017« des Berliner Beratungsunternehmens Research2guidance.»Unsere Ergebnisse zeigen, dass die lang erwartete mobile Revolution im Gesundheitswesen beginnt. Sowohl Anbieter im Gesundheitswesen als auchVerbraucher nutzen Smartphones zur Verbesserung der Gesundheitsversorgung« erläutert Ralf-Gordon Jahns, Research Director bei Research2guidance.  

https://www.rekahealth.com/index.aspx

REKA Pte Ltd, main operation in Singapore, is the developer for H'andy Sana and other mobile ECG series of products.

Mr. Frank Raymakers, Director of Sales, EuropeMr. Raymakers has over 30 years of experience in sales and marketing, with the bulk of them specializing in the medical device industry. Throughout his career, Mr. Raymakers has consistently delivered results in managing sales and distribution networks for medical devices and systems, which encompassed the ambulatory, hospital, and home-care markets. Previously, as the Sales Director at Envitec (now part of Honeywell), Mr. Raymakers took charge of expanding the markets in Europe and the Middle East. While at Envitec, he successfully increased sales under his charge by ten-fold and played a major role in the growth of the company, which in turn led to the acquisition of the company by Honeywell in 2007. Mr. Raymakers went on to serve as the Sales Director for MedX Healthcare, and subsequently Medical Marketing Berlin (MMB). During his time with these two companies, Mr. Raymakers successfully established extensive sales and distribution networks for his companies’ products in the European market, while effectively managing relationships with stakeholders in the industry, such as doctors, distributors, and pharmaceutical companies.Mr. Raymakers can be reached at frank@rekahealth.com.  

http://www.prnewswire.com/news-releases/...-technology-193824341.html  

 

Diese Form der Therapie wird nun auch von großen Health Care Unternehmen entdeckt. GE Healthcare z. B. will im Bereich Sauglingspflege die Phototherapie anwenden.

Auch in der Krebs Therapie wird diese Technologie entdeckt. Der Markt für das Produkt ist ein Milliarde Markt. Weitere Anwendungsbereiche sind wundheilung, Alzheimer, Parkinson usw.

MedX verfügt über ein umfangreiches und innovatives Produktportfolio
im HealthCare Bereich. Nun endlich werden diese Produkte und deren positive TherapieWirkung entdeckt. Für MedX dürfte damit eine aggressive Wachstumsstory in einem Multi MilliardenMarkt beginnen.

http://www.docstoc.com/docs/124686423/MEDX-ad

MedX Health Corp. (MedX) develops, manufactures and markets phototherapy devices for pain relief and tissue repair. The Company develops, manufactures and distributes low-level laser light technology and light imaging systems, for use in numerous medical settings for tissue repair, including rehab/sports medicine, dentistry, wound care, aesthetics, pain management, and imaging of suspicious moles or lesions. MedX products are used by practitioners in clinics, academic facilities, and hospitals, as well as by professional athletes and sports teams. MedX products include MedX Phototherapy Device, MedX Rehab Console System, MedX Rehab Handheld Laser, MedX superluminous diodes (SLD) Cluster, MedX Rehab Portable Laser, MedX Dental Console System, Oralase Dental Portable Laser, MedXHome System, Acupuncture Console System and Acupuncture Portable Laser. On June 15, 2011, it purchased from Biocompatibles UK Ltd, the worldwide Siascopy assets, which includes MoleMate and related technologies.2013-03-06 01:27:48


http://en.m.wikipedia.org/wiki/Light_therapy#section_5


Parkinson's disease
Bright light therapy may ease Parkinson's disease
 by reducing patients' tremors.[41]
[42]
Alzheimer's disease
A qualitative study
 conducted on a 20-person cohort
 of women and published in 2011 suggested a positive impact of light therapy on overall cognitive function
in Alzheimer's disease
 patients, a preliminary finding requiring larger andquantitative studies
 to confirm.[43]
[44]  

investox und bondjames hier schreiben ist echt mies. Hoffe dass absolut niemand auf euer Geschreibe hereinfällt und irgendetwas in dieses UN investiert. Irgendwelche scheinbar guten News von irgendwoher hier veröffentlichen, aber auf kritische Fragen nicht eingehen... meiner Meinung nach ein ganz schlechter Push-Versuch.

 

lässt grüßen lool  

 

MedX Health appoints Canitano as president, COO

2013-04-05 10:22 ET - News Release

 

 

Mr. Louie Canitano reports

MEDX NAMES LOUIE CANITANO AS PRESIDENT AND CHIEF OPERATING OFFICER

MedX  Health Corp.'s board of directors has appointed Louie Canitano as  president and chief operating officer effective immediately.

In  his new role as president and chief operating officer Mr. Canitano will  oversee all operational, financial and corporate aspects of the company  and will focus on executing the strategic plan approved by the board.  MedX's patented medical device technology for the early detection of  skin cancer is the company's leading product and as such will be the  focal point of its development and marketing strategy. This product has  the potential to create a new and substantial revenue stream for MedX.

Mr.  Canitano joined MedX in February, 2010, as executive vice-president,   operations. He has a deep understanding of operating emerging growth  medical device technology  companies, and brings to MedX over 18 years  of operational medical device experience focusing on  engineering,  proprietary intellectual property, management and corporate assignments.  Mr. Canitano is uniquely suited to  anticipate trends and quickly  respond to regulatory changes and financing challenges, and has   experience in all sectors including sales and marketing, regulatory, IP,  design and development, and also holds a  patent surrounding laser  therapy. Mr. Canitano began his career with managing G code and Schedule  5-based OHIP  physiotherapy and multidisciplinary clinics, introducing  and utilizing  laser therapy as a palliative modality. He has a bachelor  of sciences in natural health sciences.

Mr. Canitano states:  "Skin cancer represents the fastest growing form of cancer in the world  and affects all age groups. Detecting skin cancer early is the key to  long-term survival rates and therefore MedX will seek unique strategic  relationships that give ease of access to our technology. This includes  partnering with thought leaders, advocacy partners, and strategic  channel partners to ensure our technology has global reach."

We seek Safe Harbor.

Quelle: http://www.stockwatch.com/News/...2056772&symbol=MDX&region=C

 

 

MedX to file late 2012 results, requests MCTO

2013-04-12 14:27 ET - News Release

 

 

Mr. Louie Canitano reports

MEDX  ANNOUNCES ANTICIPATED DELAY IN ANNUAL FINANCIAL RESULTS FOR THE YEAR  ENDED DECEMBER                                         31, 2012

As  a result of delays in being able to obtain financing to secure fees due  to its  auditors, which financing has now been secured, MedX Health  Corp. anticipates that it will be unable to meet  its originally  scheduled filing of the annual audited consolidated financial statements  for the year ended Dec.  31, 2012, the management's discussion and  analysis for the for the year, and relevant  chief executive officer and  chief financial officer certifications within the time prescribed by  securities regulations, namely April 30,  2013. Management has taken  steps to resolve the difficulties, and believes that as a result it will   be able to file the annual audited consolidated financial statements,  management's discussion and analysis,  and CEO and CFO certifications  for the year ended Dec. 31, 2012, by May 17, 2013.

The company has  made an application to the Ontario Securities Commission, as its  principal regulator, for issuance of a management cease-trade order  pursuant to National Policy 12-203, and intends to comply with its  obligations to satisfy the provisions of the alternative information  guidelines as set out in National Policy 12-203 for so long as it  remains in default.

MedX is not the subject of any insolvency proceeding.

There is no other material information that has not been generally disclosed.

We seek Safe Harbor.

 

Quelle: http://www.stockwatch.com/News/...2058606&symbol=MDX&region=C

 

 

 

 

 

 

und was bedeutet das?  

besser gesagt, wie soll/wird das interpretiert? Ist das gut? Auf den Kurs scheints ja keine Auswirkungen zu haben...  

interpretationsansätze bleiben jedem selbst überlassen..  "MedX is not the subject of any insolvency proceeding" mal sehn was das bedeutet..

 

 

 http://www.ariva.de/news/...enture-Exchange-Cease-Trade-Order-4520919

 

 

http://www.boerse-frankfurt.de/de/aktien/...th+corp+CA5850901037/news

 

Dear ......,

 

 

Regards,

Louie Canitano

President and Chief Operating Officer

Weiters zu den Zahlen: http://www.stockwatch.com - Canada - Symbol MDX ...

 

Und dann muss der Kurs nur noch ein bisschen steigen :-)  

 

MedX Health reinstated for trading

2013-05-31 18:40 ET - Cease Trade Company Rescinded

 

 

Further to the TSX Venture Exchange bulletin dated May 6, 2013, the  exchange has been advised that the cease trade order issued by the  Ontario Securities Commission on May 6, 2013, has been revoked.

Effective at the open on Monday, June 3, 2013, trading will be reinstated in the securities of the company.

 

seen on: http://www.stockwatch.com/News/...2077406&symbol=MDX&region=C

 

 

wird unsere medx jetzt schon übernommen ?

BC Technical Acquires MEDX

http://www.prnewswire.com/news-releases/...quires-medx-210687151.html